|
KR20120123443A
(ko)
*
|
2010-01-27 |
2012-11-08 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
|
|
UA126465C2
(uk)
|
2011-06-10 |
2022-10-12 |
Ханмі Сайенс Ко., Лтд. |
Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
|
|
RU2607365C2
(ru)
|
2011-06-17 |
2017-01-10 |
Ханми Сайенс Ко., Лтд. |
Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
|
|
CN105601748B
(zh)
|
2011-07-01 |
2021-08-27 |
恩格姆生物制药公司 |
用于代谢病症和疾病治疗的组合物、应用和方法
|
|
AU2012311484B2
(en)
|
2011-09-23 |
2017-04-13 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
WO2014073842A1
(en)
|
2012-11-06 |
2014-05-15 |
Hanmi Pharm. Co., Ltd. |
Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
HK1214832A1
(zh)
|
2012-11-28 |
2016-08-05 |
恩格姆生物制药公司 |
用於代謝病症和疾病治療的組合物和方法
|
|
ES2915851T3
(es)
|
2012-12-27 |
2022-06-27 |
Ngm Biopharmaceuticals Inc |
Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
EP2986313B1
(en)
|
2013-04-18 |
2019-06-12 |
Novo Nordisk A/S |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
|
SI3004155T1
(sl)
|
2013-05-28 |
2022-02-28 |
Takeda Pharmaceutical Company Limited |
Peptidna spojina
|
|
WO2015035419A1
(en)
*
|
2013-09-09 |
2015-03-12 |
Hoffmann-La Roche Inc. |
Dosages of gip/glp-1 co-agonist peptides for human administration
|
|
JP6822839B2
(ja)
*
|
2013-09-13 |
2021-01-27 |
ザ・スクリップス・リサーチ・インスティテュート |
修飾された治療剤、及びその組成物
|
|
CA2927592C
(en)
|
2013-10-28 |
2020-08-18 |
Ngm Biopharmaceuticals, Inc. |
Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
|
|
US10626156B2
(en)
|
2013-12-06 |
2020-04-21 |
Jie Han |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
|
KR102455171B1
(ko)
|
2013-12-18 |
2022-10-14 |
더 스크립스 리서치 인스티튜트 |
변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
|
|
AR098616A1
(es)
|
2013-12-18 |
2016-06-01 |
Lilly Co Eli |
Péptido para el tratamiento de hipoglicemia severa
|
|
PE20170256A1
(es)
|
2014-01-24 |
2017-04-22 |
Ngm Biopharmaceuticals Inc |
Proteinas de union y sus metodos de uso
|
|
TW201625669A
(zh)
*
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
WO2015183890A2
(en)
|
2014-05-28 |
2015-12-03 |
Ngm Biopharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders and diseases
|
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
|
AU2015277438B2
(en)
|
2014-06-16 |
2020-02-27 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
CN106574926B
(zh)
*
|
2014-08-06 |
2019-04-19 |
雀巢产品技术援助有限公司 |
用于预测体重减轻程度的生物标志物
|
|
ES2685987T3
(es)
|
2014-09-05 |
2018-10-15 |
University Of Copenhagen |
Análogos de péptidos gip
|
|
TWI802396B
(zh)
|
2014-09-16 |
2023-05-11 |
南韓商韓美藥品股份有限公司 |
長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
|
|
RU2729161C2
(ru)
|
2014-10-23 |
2020-08-04 |
ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. |
Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
|
|
CN107108715A
(zh)
|
2014-10-24 |
2017-08-29 |
默沙东公司 |
胰高血糖素和glp‑1受体的共激动剂
|
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
JP2018012644A
(ja)
*
|
2014-11-26 |
2018-01-25 |
武田薬品工業株式会社 |
ペプチド化合物
|
|
KR102418477B1
(ko)
|
2014-12-30 |
2022-07-08 |
한미약품 주식회사 |
글루카곤 유도체
|
|
TWI582109B
(zh)
*
|
2015-01-09 |
2017-05-11 |
美國禮來大藥廠 |
Ｇｉｐ及ｇｌｐ－１共促效劑化合物
|
|
KR101669140B1
(ko)
|
2015-04-28 |
2016-10-26 |
(주)케어젠 |
항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
|
|
US10800843B2
(en)
|
2015-07-29 |
2020-10-13 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho-binding proteins
|
|
TWI622596B
(zh)
|
2015-10-26 |
2018-05-01 |
美國禮來大藥廠 |
升糖素受體促效劑
|
|
JP6728352B2
(ja)
|
2015-11-09 |
2020-07-22 |
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド |
胆汁酸に関係した障害の治療方法
|
|
ES2983409T3
(es)
*
|
2016-03-10 |
2024-10-23 |
Medimmune Ltd |
Agonista de Glp-1/glucagón para su uso en el tratamiento de la esteatohepatitis no alcohólica
|
|
JP6995042B2
(ja)
|
2016-05-24 |
2022-02-04 |
武田薬品工業株式会社 |
ペプチド化合物
|
|
CA3034399A1
(en)
|
2016-08-26 |
2018-03-01 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
CN109200273B
(zh)
*
|
2017-07-04 |
2021-02-19 |
中国药科大学 |
一种多肽用于制备预防或治疗脂肪肝病药物的用途
|
|
JOP20190211A1
(ar)
|
2017-03-31 |
2019-09-15 |
Takeda Pharmaceuticals Co |
ببتيد منشط لمستقبل gip
|
|
KR102743887B1
(ko)
*
|
2017-05-31 |
2024-12-19 |
유니버시티 오브 코펜하겐 |
장기-작용성 gip 펩타이드 유사체
|
|
US10470311B2
(en)
*
|
2017-09-28 |
2019-11-05 |
Juniper Networks, Inc. |
Clearance size reduction for backdrilled differential vias
|
|
CA3078652A1
(en)
|
2017-10-12 |
2019-04-18 |
Novo Nordisk A/S |
Semaglutide in medical therapy
|
|
US11633459B2
(en)
|
2018-05-04 |
2023-04-25 |
Novo Nordisk A/S |
GIP derivatives and uses thereof
|
|
SG11202100112YA
(en)
*
|
2018-07-23 |
2021-02-25 |
Lilly Co Eli |
Methods of using a gip/glp1 co-agonist for therapy
|
|
SG11202105586YA
(en)
|
2018-12-03 |
2021-06-29 |
Antag Therapeutics Aps |
Modified gip peptide analogues
|
|
CN109379770B
(zh)
*
|
2018-12-11 |
2021-04-06 |
北京百瑞互联技术有限公司 |
蓝牙mesh网络的路径辅助候选节点的优选方法、装置及节点
|
|
AU2020206388B2
(en)
|
2019-01-07 |
2022-12-01 |
Vitalixir (Beijing) Co., Ltd |
Novel polypeptide and therapeutic uses thereof
|
|
WO2021083306A1
(zh)
*
|
2019-10-31 |
2021-05-06 |
东莞市东阳光生物药研发有限公司 |
Glp-1/gcg双受体激动剂多肽
|
|
MX2022006861A
(es)
|
2019-12-04 |
2022-07-11 |
Scripps Research Inst |
Agonistas del receptor glp2 y metodos de uso.
|
|
CN114945589B
(zh)
*
|
2020-02-24 |
2024-05-24 |
深圳市图微安创科技开发有限公司 |
多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用
|
|
US20230263896A1
(en)
*
|
2020-07-06 |
2023-08-24 |
Vitalixir (Beijing) Co., Ltd |
Novel polypeptide and therapeutic use thereof
|
|
US20230346961A1
(en)
*
|
2020-07-22 |
2023-11-02 |
Novo Nordisk A/S |
Glp-1 and gip receptor co-agonists
|
|
EP4185607A1
(en)
*
|
2020-07-22 |
2023-05-31 |
Novo Nordisk A/S |
Co-agonists at glp-1 and gip receptors suitable for oral delivery
|
|
EP4197560A4
(en)
*
|
2020-08-14 |
2025-11-26 |
Hanmi Pharmaceutical Co Ltd |
Pharmaceutical composition comprising a persistent triple activator conjugate used as the active ingredient.
|
|
EP4230640A4
(en)
*
|
2020-10-16 |
2024-11-20 |
Hanmi Pharm. Co., Ltd. |
GLP-1/GIP DOUBLE AGONIST, LONG-ACTING CONJUGATE THEREOF AND PHARMACEUTICAL COMPOSITION THEREOF
|
|
MX2023006419A
(es)
*
|
2020-12-02 |
2023-08-15 |
Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd |
Compuestos polipéptidos modificados con lactama.
|
|
CN114891071A
(zh)
*
|
2020-12-08 |
2022-08-12 |
鸿绪生物科技(嘉善)有限公司 |
新型多肽及其治疗用途
|
|
CN114617956B
(zh)
*
|
2020-12-10 |
2023-10-03 |
江苏中新医药有限公司 |
一种高效降糖的蛋白质药物
|
|
US12281149B2
(en)
|
2021-05-13 |
2025-04-22 |
Carmot Therapeutics, Inc. |
Modulators of G-protein coupled receptors
|
|
KR20240032010A
(ko)
|
2021-06-09 |
2024-03-08 |
더 스크립스 리서치 인스티튜트 |
장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법
|
|
US20250115654A1
(en)
*
|
2021-11-12 |
2025-04-10 |
Fujian Shengdi Pharmaceutical Co., Ltd. |
Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
|
|
TW202330584A
(zh)
|
2022-01-20 |
2023-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
前藥及其用途
|
|
CN116143884B
(zh)
*
|
2023-02-03 |
2023-08-04 |
江苏师范大学 |
一类长效GLP-1/glucagon/GIP受体三重激动剂及其应用
|
|
KR20260005268A
(ko)
*
|
2023-04-23 |
2026-01-09 |
카모트 테라퓨틱스 인크. |
당뇨병 치료
|
|
WO2026046202A1
(zh)
*
|
2024-08-26 |
2026-03-05 |
博瑞生物医药（苏州）股份有限公司 |
Glp-1/gip肽或含有其的药物组合物的用途
|
|
WO2026046328A1
(en)
*
|
2024-08-30 |
2026-03-05 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Dosing regimen of glp-1 conjugates
|